Biotech

All Articles

Transgene's viral cancer cells vaccination flunks midphase test

.Transgene's therapeutic vaccine applicant TG4001 has actually failed a period 2 strong lump trial. ...

Upstream swells IPO to $255M as it details together with CAMP4

.Upstream Bio has swollen its IPO to $255 thousand as the company joins CAMP4 Therapeutics this morn...

Sanofi flunks MS study, dealing an additional impact to Denali contract

.Sanofi has actually ceased a period 2 ordeal of Denali Therapeutics-partnered oditrasertib in vario...

Turnstone lays off 60%, agitates C-suite to stretch out money

.Turnstone Biologics is minimizing its head count through 60% and also shocking its own C-suite if y...

Gilead surrenders on $15M MASH wager after weighing preclinical information

.In a year that has observed an authorization and a raft of readouts for metabolic dysfunction-assoc...

Texas biotech axes cancer cells pact, pins wishes on excessive weight

.Alaunos Rehabs is actually axing an arrangement along with Precigen, quiting licensing rights to a ...

Capricor portions extra information for DMD treatment after launching BLA

.Capricor Rehabs is taking a triumph lap for their stage 2 Duchenne muscular dystrophy (DMD) trial. ...

FDA spots Kezar lupus trial in grip complying with 4 client fatalities

.The FDA has put Kezar Life Sciences' lupus trial on hold after the biotech flagged 4 fatalities dur...

Phase 3 Intellectual Stone test hits SMA objective, delivering stockpile 200%

.A phase 3 test of Academic Rock's spinal muscular degeneration (SMA) prospect has struck its main e...

CAMP 4 is most current to eye IPO, while Upstream spells out $182M strategy

.RNA biotech CAMP4 Therapeutics has actually defined think about a $67 million IPO, along with infla...